Opus Genetics (IRD) Common Equity (2010 - 2026)

Opus Genetics (IRD) has reported Common Equity for 17 consecutive years, with -$45.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity fell 1003.53% year-over-year to -$45.8 million; the TTM figure through Mar 2026 stood at -$45.8 million (down 1003.53% YoY), while the FY2025 annual figure was $15.3 million, up 128.26% from the prior year.
• Common Equity retreated to -$45.8 million in Q1 2026 per IRD's latest filing, from $15.3 million in the prior quarter.
• Across five years, Common Equity topped out at $50.3 million in Q3 2023 and bottomed at -$45.8 million in Q1 2026.
• Historically, Common Equity has averaged $23.2 million across 5 years, with a median of $17.5 million in 2025.
• Annual changes were most pronounced in 2023 — Common Equity surged 323.36% — and 2026, when it plunged 1003.53%.
• Opus Genetics' Common Equity stood at $46.2 million in 2022, then climbed by 7.93% to $49.9 million in 2023, then sank by 86.53% to $6.7 million in 2024, then jumped by 128.26% to $15.3 million in 2025, then tumbled by 398.64% to -$45.8 million in 2026.
• Business Quant data shows IRD's Common Equity at -$45.8 million in Q1 2026, $15.3 million in Q4 2025, and $6.0 million in Q3 2025.